# Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

> **NCT04196010** · PHASE1 · TERMINATED · sponsor: **University of Washington** · enrollment: 13 (actual)

## Conditions studied

- Myeloid Neoplasm
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **BIOLOGICAL:** Recombinant Granulocyte Colony-Stimulating Factor
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT04196010
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-08
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-10-13
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Terminated due to unfavorable risk-benefit ratio of investigational regimen.
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196010, "Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04196010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*